<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234985</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0351</org_study_id>
    <nct_id>NCT03234985</nct_id>
  </id_info>
  <brief_title>Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia</brief_title>
  <acronym>NUCLARA</acronym>
  <official_title>Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and&#xD;
      consolidation. Standard chemotherapy combination for induction treatment associates&#xD;
      cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About&#xD;
      60-70% of patients achieved complete remission after this standard chemotherapy. As&#xD;
      cytarabine competes with endogenous nucleotides to exert its activity, the aim of this&#xD;
      protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of&#xD;
      the induction treatment. Thus, intracellular nucleotides levels will be determined in&#xD;
      peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment,&#xD;
      and results will be compared with the efficacy of the treatment. This parameter will be&#xD;
      assessed by the achievement of complete remission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>30 days</time_frame>
    <description>Primary endpoint will be the achievement of complete remission after induction treatment and bone marrow aplasia.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>acute myeloid leukemia patients</arm_group_label>
    <description>Patients over 18 years with acute myeloid leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological analyses</intervention_name>
    <description>Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.</description>
    <arm_group_label>acute myeloid leukemia patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients or healthy volunteers over 18 years with acute myeloid leukemia (except acute&#xD;
        myeloid leukemia3)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients Inclusion Criteria:&#xD;
&#xD;
          -  age over 18 years&#xD;
&#xD;
          -  acute myeloid leukemia&#xD;
&#xD;
          -  standard induction chemotherapy with cytarabine and daunorubicin&#xD;
&#xD;
          -  patients who received the information and did not object to participate to the study&#xD;
&#xD;
        Patients Exclusion Criteria:&#xD;
&#xD;
        - patients with acute myeloid leukemia 3&#xD;
&#xD;
        healthy volunteers Inclusion Criteria :&#xD;
&#xD;
          -  adults without known hematological disease,&#xD;
&#xD;
          -  adults who received the information and did not object to participate in the study&#xD;
&#xD;
        healthy volunteers Exclusion Criteria :&#xD;
&#xD;
        - Volunteers with known hematological disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier THOMAS, MD</last_name>
    <phone>04 78 86 22 40</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.thomas@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle MACHON, PharmD</last_name>
    <phone>04 72 66 64 00</phone>
    <phone_ext>+33</phone_ext>
    <email>christelle.machon@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'hématologie - Centre Hospitalier Lyon Sud - Hospices Civils de LYON</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier THOMAS, MD</last_name>
      <phone>04 78 86 22 40</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.thomas@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christelle MACHON, PharmD</last_name>
      <phone>04 72 66 64 00</phone>
      <phone_ext>+33</phone_ext>
      <email>christelle.machon@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier THOMAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

